Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Lymphoma
•
NCI-CCC Tumor Board Question
•
Hematology
•
NCI-CCC Lymphoma Tumor Board Question
•
City of Hope
How would you treat a tDLBCL originally treated with R-CHOP who relapses with DLBCL 15 years after the original diagnosis?
Related Questions
In light of data from TRIANGLE, ECHO, and ENRICH, what is the best strategy to treat newly diagnosed patients with the blastoid variant MCL?
How would you manage a patient with a recent diagnosis of advanced DLBCL (non-GCB subtype) who has baseline grade 3 neuropathy?
How would you manage a frail patient with GCB DLBCL who is unable to complete R-CHOP but has moderate residual disease?
How would you manage a patient w/ blastoid variant MCL given data w/ all the current BTKi regimens TRIANGLE, BOVEN, and TRAVERSE
How would you manage a patient with primary CNS lymphoma who received R-MTX followed by autologous transplant with systemic relapse 5 years later for which R-Pola-CHP was given now followed by CNS relapse?
What is the role of surveillance imaging after first line therapy in patients with aggressive lymphomas?
How would you manage a healthy young adult patient with nodular lymphocyte predominant Hodgkin lymphoma with steroid-responsive severe hemolytic anemia and no other symptoms?
Do you utilize ctDNA-based MRD testing after frontline chemotherapy for DLBCL?
How would you manage a stage IE Burkitt lymphoma with stable disease after three cycle of DA-R-EPOCH?
Has the data for the ENRICH study changed your practice for the initial treatment of mantle-cell lymphoma?
